Tin tức & Cập nhật

Original New Drug Application Approvals by US FDA (1-15 April 2024)

New drug applications approved by US FDA as of 1-15 April 2024 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

SGLT2 inhibitors a promising gout medication in T2D

The use of sodium-glucose cotransporter type 2 (SGLT2) inhibitors lowers the risk of incident gout or recurrent gout flares among patients with type 2 diabetes who are taking metformin, as shown in a study.

Do GLP1 receptor agonists increase thyroid cancer risk?

Use of glucagon-like peptide 1 (GLP1) receptor agonists does not contribute to an elevated risk of thyroid cancer, as shown in a Scandinavian cohort study with a mean follow-up of nearly 4 years.

Keeping blood sugar under control reduces CRC risk in people with diabetes

For individuals with diabetes mellitus (DM), optimal glycaemic control may protect against the risk of developing colonic adenoma and colorectal cancer (CRC), as reported in a population-based cohort study.

Is it safe to use GLP1 agonists, SGLT2 inhibitors in patients on multiple insulin injections?

Patients using multiple insulin injections demonstrate no significant difference in changes to A1c, insulin requirements, or weight after a year of treatment with a sodium glucose transporter 2 (SGLT2) inhibitor or glucagon-like peptide 1 (GLP1) receptor agonist, as shown in a study.

GLP-1RAs may improve long-term liver outcomes in T2D patients with MASLD

For patients with type 2 diabetes (T2D) and metabolic dysfunction-associated steatotic liver disease (MASLD) cirrhosis, treatment with glucagon-like peptide-1 receptor agonists helps reduce the risk of hepatic decompensation, portal hypertension, hepatocellular carcinoma, and liver transplantation, according to a study.

[MIMS Education] Tổng quan về đau bụng kinh - P1